No Detail Found!

Histological Findings in Antigen E Positive and Negative in Chronic Hepatitis B

Author(s)
Mustafa Zanyar Akkuzu Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital,Diyarbakir,Turkiye
Berat Ebik Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital,Diyarbakir,Turkiye
Ferhat Bacaksiz Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital,Diyarbakir,Turkiye
Ali Uzel Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital,Diyarbakir,Turkiye
Ahmet Yavuz Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital,Diyarbakir,Turkiye
Umit Karabulut Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital,Diyarbakir,Turkiye
Abstract
Objective: To determine the histopathological ndings in patients with HBeAg-positive chronic HBV infection (immunotolerant phase in old terminology) and HBeAg-negative chronic HBV infection (inactive carrier phase in old terminology). Study Design: Observational study. Place and Duration of the Study: Department of Gastroenterology, University of Health Sciences, Diyarbakir Gazi Yasargil Education and Research Hospital, Diyarbakir, Turkiye and Diyarbakir and Mersin University School of Medicine, Diyarbakir, Turkiye, from May 2014 to August 2022. Methodology: The di erence between brosis and histological activity indices of 289 patients in the immunotolerant and inactive carrier phase who had liver biopsy was examined statistically. Additionally, the relationship of these data with age and gender was investigated. Results: While 236 (81.7%) of the patients were in the inactive carrier phase, 53 (18.3%) patients were in the immunotolerant phase. The mean brosis score of patients in the immunotolerant stage was 2.0 ± 1.2, while it was 2.0 ± 1.0 in inactive carriers (p = 0.753). The number of patients with a brosis score of two and above was 21 (39.6%) in immunotolerant patients and 52 (22.0%) in inactive carrier patients (p = 0.004). In patients under 30 years of age, the mean brosis score was 1.7 ± 1.0. It was 2.0 ± 1.1 in those over 30 years of age (p = 0.016). Conclusion: Biochemical parameters or viral load cannot clearly re ect cellular damage in the liver. In the future, HBV DNA positivity alone may be the only criterion for the treatment.
Publication Details
Page(s) 891-896
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
fibrosis, Chronic viral hepatitis B, Immune tolerance phase, Inactive carrier phase
0

Citations

0

Downloads

64

Views